ArticleBMC complementary medicine and therapies2026
Personalized barrier recovery induced by Lactobacillus helveticus SBT2171 in an In Vitro model of ulcerative colitis-derived fecal supernatants.
Article in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDisruption of the intestinal epithelial barrier is a hallmark of inflammatory bowel disease (IBD). Although probiotics and postbiotics are increasingly recognized as potential therapeutic approaches, treatment efficacy is often influenced by patient-specific variability.
methodsIn this study, intestinal inflammation was modeled by exposing HT-29 cells to fecal supernatants (FS) derived from three patients with ulcerative colitis (UC). The expression of pro-inflammatory (IL-8) and barrier-associated (Claudin-1, MUC2) genes was assessed by real-time PCR. Subsequently, the restorative effects of different preparations of Lactobacillus helveticus SBT2171, including live bacteria, cell-free supernatant, and debris-containing supernatant, were evaluated at 24 and 48 h.
resultsFS exposure significantly upregulated IL-8 expression while downregulating Claudin-1 and MUC2, thereby recapitulating IBD-associated epithelial disruption. Treatment with L. helveticus preparations partially restored barrier-related gene expression in a patient- and treatment-dependent manner. Live bacteria induced transient or sustained Claudin-1 upregulation depending on the FS source, whereas the cell-free supernatant demonstrated broader and more durable restorative effects across distinct inflammatory contexts. In contrast, debris-containing preparations exerted limited or even suppressive effects, particularly on MUC2 expression.
conclusionsThese findings demonstrate that the barrier-restorative effects of L. helveticus in vitro is not uniform but shaped by the unique inflammatory and microbial environment of each patient. Collectively, our results support the potential of postbiotic formulations as safer and effective modulators of epithelial barrier repair and underscore the need for personalized strategies in microbiota-based therapies for IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.